Comparative Pharmacology
Head-to-head clinical analysis: KLOTRIX versus SLOW K.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KLOTRIX versus SLOW K.
KLOTRIX vs SLOW-K
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KLOTRIX is a combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic. The ARB component blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. The thiazide diuretic increases sodium and water excretion by inhibiting the sodium-chloride cotransporter in the distal convoluted tubule of the kidney.
Potassium is the major intracellular cation; essential for maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function.
Adults: 500-1000 mg orally every 6 hours; maximum 4000 mg/day.
Adults: 600-2400 mg potassium chloride (8-32 mmol K+) orally per day in divided doses, usually 1-2 tablets twice daily. Maximum single dose: 20 mmol. Route: oral. Frequency: 1-4 times daily.
None Documented
None Documented
Terminal half-life 12 hours; prolonged to 24–30 hours in moderate renal impairment (CrCl <50 mL/min)
Not applicable; potassium is an electrolyte with no defined elimination half-life; distribution half-life ~2-4 hours
Renal 70% as unchanged drug, fecal 30% via biliary secretion
Primarily renal (>90%) as potassium ions; minimal biliary/fecal elimination (<5%)
Category C
Category C
Potassium Supplement
Potassium Supplement